Deliver Your News to the World

Lung Cancer Medical Breakthrough (OTC:BMOD)


StocksHaven Investments profiles one of the most promising up and coming small cap biotech companies, Biomoda Inc, which has established a medical breakthrough for early lung cancer detection. It is a development-stage company. The Company is an invitro diagnostics company that develops assays, or tests, to detect cancer. These assays are performed in clinical reference laboratories using body-fluid samples. This technology is based on a licensed patent from Los Alamos National Laboratories. The technology is based on a molecule that has an affinity to bind with cancer cells and it fluoresces red under ultra violet light. It is a porphyrin molecule. This technology works with a range of cell types. The Company is in the process of developing a line of assays for a variety of cancers based on adaptations of this technology. Biomoda’s first product is an assay for lung cancer.

Before reading this analysis, it is important to note that there currently is no commercial early stage lung cancer diagnostic of proven effectiveness. The proprietary test developed by Biomoda is truly without peer. Of the few known alternatives, none embody the elements of high sensitivity and accuracy at the cellular level, simple noninvasive use and very affordable cost – all key to rapid and broad commercial acceptance. Their process is truly revolutionary.

The full special report on the company appears at

To feature your publicly traded company in Alerts or as a fully profiled company, email us at

Disclosure: Position in BMOD


About StocksHaven Investments

StocksHaven Investments can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 otc bmod
 biomoda inc
 biomoda lung cancer treat

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.